BERLIN, Germany – June 9, 2026
Pentixapharm Holding AG has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application, enabling the launch of the Phase 3 PANDA clinical study for its lead CXCR4-targeted cardiovascular diagnostic program. The authorization allows the company to initiate a U.S.-focused, multicenter Phase 3 trial evaluating [⁶⁸Ga]Ga-PentixaFor PET/CT imaging in patients with treatment-resistant hypertension associated with primary aldosteronism, one of the most common yet significantly underdiagnosed endocrine causes of high blood pressure. The FDA clearance represents a critical step in Pentixapharm’s regulatory strategy and positions the company to advance a potentially first-in-class cardiovascular diagnostic platform capable of transforming disease detection, patient stratification, and treatment selection. With growing awareness of primary aldosteronism and expanding screening recommendations worldwide, the PANDA program addresses a substantial unmet medical need while targeting a rapidly evolving cardiovascular diagnostics market.
Phase 3 PANDA Study Targets an Underdiagnosed Cause of Hypertension
The Phase 3 PANDA study has been specifically designed to evaluate Pentixapharm’s innovative imaging technology as a non-invasive method for identifying and classifying patients with primary aldosteronism. This endocrine disorder is increasingly recognized as a major contributor to secondary hypertension and may affect 5% to 14% of all patients with hypertension and up to 30% of those with resistant hypertension. Despite its prevalence, primary aldosteronism remains substantially underdiagnosed due to limitations in current diagnostic approaches. A particularly important challenge is distinguishing between unilateral and bilateral disease, as treatment strategies differ significantly. Patients with unilateral disease may benefit from surgical removal of the affected adrenal gland, while bilateral disease typically requires lifelong medical therapy.
The PANDA study aims to demonstrate that CXCR4-targeted PET/CT imaging can provide more accurate disease characterization and support improved treatment decision-making. The trial design was developed in close alignment with FDA guidance, including recommendations obtained during a formal Type B pre-IND meeting, supporting a regulatory pathway toward potential future approval.
First-in-Class CXCR4 Imaging Technology Shows Clinical Promise
Advertisement
At the heart of the PANDA program is [⁶⁸Ga]Ga-PentixaFor, a novel gallium-68 labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 using high-resolution PET/CT imaging. Scientific research has demonstrated significant CXCR4 overexpression in aldosterone-producing adrenal tumors, making the receptor an attractive target for diagnostic imaging. Clinical experience involving more than 2,000 patients across multiple indications has already demonstrated the technology’s ability to non-invasively image CXCR4 expression in vivo. By directly visualizing disease-related biological activity, Pentixapharm believes the technology may offer a more reliable and precise approach to disease subtyping compared with existing diagnostic methods.
This capability could improve patient selection, reduce diagnostic uncertainty, and help clinicians identify patients most likely to benefit from surgical intervention or targeted medical treatment. The platform also highlights the growing role of precision imaging technologies in cardiovascular and endocrine disease management.
Regulatory Milestone Strengthens Commercial and Clinical Potential
The FDA’s IND clearance marks a significant achievement for Pentixapharm and reinforces confidence in the company’s registrational development strategy. Company executives described the approval as an important validation of both the technology platform and the underlying clinical development plan. Pentixapharm has already established manufacturing and supply-chain infrastructure designed to support large-scale clinical execution and future commercialization activities. Beyond its immediate clinical significance, the PANDA program represents a potentially valuable commercial opportunity within the expanding precision diagnostics market.
As awareness of primary aldosteronism continues to increase and healthcare systems place greater emphasis on earlier disease detection and personalized treatment approaches, demand for advanced diagnostic solutions is expected to grow substantially. With the Phase 3 PANDA study now authorized to begin in the United States, Pentixapharm is positioned to advance one of the most innovative cardiovascular diagnostic programs currently in development while seeking to improve outcomes for millions of patients affected by treatment-resistant hypertension and related endocrine disorders.
Source: Pentixapharm press release
